|
Aug 4
|
Why Morgan Stanley Upgraded This Biotech Stock to a Buy
|
|
Aug 1
|
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations
|
|
Jul 31
|
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
|
|
Jul 31
|
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
|
|
Jul 30
|
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
|
|
Jul 30
|
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
|
|
Jul 30
|
Ionis Pharmaceuticals: Q2 Earnings Snapshot
|
|
Jul 30
|
Ionis reports second quarter 2025 financial results and highlights progress on key programs
|
|
Jul 29
|
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency
|
|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 23
|
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
|
|
Jul 21
|
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
|
|
Jul 16
|
Ionis to hold second quarter 2025 financial results webcast
|
|
Jul 14
|
Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 | Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments
|
|
Jul 2
|
Nike upgraded, Sportradar initiated: Wall Street’s top analyst calls
|
|
Jun 28
|
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
|
|
Jun 27
|
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
|
|
Jun 25
|
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
|
|
Jun 25
|
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
|